Skip to main content
TipRanks
Go Ultimate75% OFF

Haemonetics (HAZ) AI Stock Analysis

1 Followers
DE:HAZ

Haemonetics

(Frankfurt:HAZ)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Recurring Consumables ModelHaemonetics combines equipment placements with recurring proprietary disposable purchases, creating procedure-linked revenue after systems are installed. This razor-and-blades model can deepen customer retention, improve revenue visibility, and support durable growth as collection volumes and device utilization expand.
Negative Factors
Higher LeverageThe increase in debt relative to equity raises financial risk and reduces flexibility if operating conditions weaken. Higher leverage can constrain capital allocation, increase sensitivity to interest costs, and make it harder to absorb execution issues during the company’s investment cycle.

Haemonetics (HAZ) vs. iShares MSCI Germany ETF (EWG)

-40%-20%0%20%40%60%80%DE:HAZ+59.42%EWG+1.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 5.47B
Dividend Yield
―
Average Volume (3M)
12
Price to Earnings (P/E)
52.9
Beta (1Y)
-0.06
Revenue Growth
-1.20%
EPS Growth
-37.57%
Country
Germany
Employees
3,009
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Haemonetics Business Overview & Revenue Model

Company Description

Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automat...

Haemonetics Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q2-2027)|% Change Since:3.77%|Next Earnings Date:Feb 11, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. The company reported double-digit organic growth in several areas, raised full-year revenue guidance, expanded its CSL relationship, advanced multiple product launches and regulatory approvals, and generated substantial cash flow. The main challenges were lower expected operating margin expansion, higher operating expenses and ramp-related costs, modest weakness in other apheresis, and uncertainty around second-half plasma collection volumes. Management nevertheless expressed confidence in the long-term growth runway and future operating leverage.

Positive Updates

Strong Second-Quarter and First-Half Performance
Organic revenue growth was 10% in the second quarter and 8% in the first half. Adjusted earnings per share was $1.35 in the quarter and $2.49 in the first half, with adjusted EPS growth of 6% in both periods.

Negative Updates

Operating Margin Growth Outlook Reduced
Second-quarter adjusted operating margin declined 40 basis points year over year to 26.3%, and first-half adjusted operating margin declined 50 basis points to 24.9%. Fiscal 2027 adjusted operating margin expansion guidance was reduced to 0-50 basis points from 50-100 basis points.

Company Guidance

For fiscal 2027, Haemonetics reaffirmed MedSurg organic revenue growth guidance of mid-single digits and raised apheresis organic revenue growth guidance to high single digits from low to mid-single digits; total company organic growth guidance increased to 6%-9% from 4%-7%, and reported growth guidance to 8%-11% from 5%-8%. The company now expects adjusted operating margin expansion of 0-50 basis points, compared with 50-100 basis points previously, and adjusted earnings per diluted share growth in line with its increased reported revenue growth guidance of 8%-11%. Free cash flow conversion is expected to be in excess of 80% of adjusted net income, with second-half growth weighted towards Q4, and guidance does not include any incremental revenue contribution from second-half plasma collections growth.

Haemonetics Risk Analysis

Haemonetics disclosed 38 risk factors in its most recent earnings report. Haemonetics reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Haemonetics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:HAZ against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MDTMDT81Outperform$128.70B24.5010.60%2.86%9.77%12.28%
BIOBIO78Outperform$9.93B9.4014.07%―1.38%―
LIVNLIVN77Outperform$5.07B25.3415.35%―11.71%―
ABTABT67Neutral$179.90B38.159.11%2.45%10.00%-66.06%
CERSCERS57Neutral$383.71M-47.68-10.54%―13.74%56.08%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%DE:HAZABTBIOCERSMDTLIVNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:HAZ and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:HAZHaemonetics110.0041.5060.58%
ABTAbbott Laboratories103.00-21.11-17.01%
BIOBio-Rad Laboratories358.9036.4211.29%
CERSCerus Corporation1.850.169.47%
MDTMedtronic99.940.050.05%
LIVNLivaNova PLC90.7330.2750.07%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.